GSK and Vir Biotechnology announced Friday that they have applied to the US Food and Drug Administration (FDA) for emergency use approval of a monoclonal antibody drug for use in the early stages of COVID-19.
A drug called VIR-7831 is intended for people over 12 years of age who have mild to moderate symptoms of COVID-19, whose condition is at risk of worsening.
Preliminary results of clinical trials on the drug, released in March, showed that administration of the drug was associated with 85% of the drug administration. reduced risk of hospitalization and death compared to the group that did not receive this therapy.
- The antibody cocktail protects against the severe course of COVID-19. «Phenomenal results»
Laboratory studies also suggest that the agent works against all dangerous variants of the coronavirus.
The companies based in London and San Francisco said they would “continue discussions” with the European Medicines Agency (EMA) and other regulators to get the drug approved for worldwide use.
- How to treat COVID-19 at home? These drugs must not be taken
Read also:
- There would be no third wave if we were testing people coming back from the UK? The expert replies
- The doctor warns: in April there may be a wave of PIMS cases in children
- Doctors have indicated places where it is easiest to get infected with the coronavirus
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.Now you can use e-consultation also free of charge under the National Health Fund.